Current issues of targeted therapy in metastatic triple-negative breast cancer

Breast Care

Volumn 6, Issue 3, 2011, Pages 234-239

  Liedtke, Cornelia ^a   Kiesel, Ludwig ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Anti angiogenic agents; Clinical trials; mTNBC; PARP inhibitors; Triple negative breast cancer

Indexed keywords

8 FLUORO 3,4 DIHYDRO 2 [4 (METHYLAMINOMETHYL)PHENYL]PYRROLO[3,4,5 E,F][2]BENZAZEPIN 6(5H) ONE; ANTHRACYCLINE; BEVACIZUMAB; BMN 673; BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; CEP 9722; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; GEMCITABINE; GPI 21016; GRANULOCYTE COLONY STIMULATING FACTOR; INIPARIB; INO 1001; MK 4827; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PF 0367338; SUNITINIB; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN; VELIPARIB;

BREAST CARCINOGENESIS; CANCER ADJUVANT THERAPY; DISEASE ASSOCIATION; DNA REPAIR; GENE EXPRESSION; GENE MUTATION; HAND FOOT SYNDROME; HUMAN; PALLIATIVE THERAPY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH;

EID: 79959866196     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000328964     Document Type: Review

References (25)

1. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N: Triple-negative breast cancer-current status and future directions. Ann Oncol 2009;20:1913-1927.
2. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L: Response to neoad-juvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-1281.
3. Carey L, Winer E, Viale G, Cameron D, Gianni L: Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol;7:683-692.
4. Gray R, Bhattacharya S, Bowden C, Miller K, Comis RL: Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009;27:4966-4972.
5. Linderholm BK, Hellborg H, Johansson U, Elmberger G, Skoog L, Lehtio J, Lewensohn R: Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol 2009;20:1639-1646.
6. O'Shaughnessy J, Romieu G, Diéras V, Byrtek M, Duenne A-A, Miles D: Meta-analysis of patients with triple-negative breast cancer (TNBC) from three randomized trials of first-line bevacizumab (BV) and chemotherapy treatment for metastatic breast cancer (MBC). Cancer Res 2010;70:452s.
7. O'Shaughnessy J, Miles D, Gray RJ, Dieras V, Perez E, Zon R, Cortes J, Zhou X, Phan S, Miller K: A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J Clin Oncol 2010;28:suppl; abstr 1005.
8. Pritchard KI, Thomssen C, Pierga JY, Cortes-Funes H, Biganzoli L, Guan Z, Manikhas G, Jendiroba D, Uziely B, Boyle F, Jagiello-Gruszfeld A, Van Arkel C, Tung Y, Dunne AA, Smith IE: Final overall survival results, including analysis of patients with triple-negative disease and aged ≥ 70 years, from the Athena study evaluating first-line bevacizumab-containing therapy for locally recurrent/metastatic breast cancer. Cancer Res 2010;70:236s.
9. Von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Gerber B, Jackisch C, Kunz G, Blohmer JU, Huober J, Hauschild M, Fehm T, Loibl S, Nekljudova V, Untch M: Neoadjuvant chemotherapy with or without bevacizumab: primary efficacy endpoint analysis of the GEPARQUINTO study (GBG 44). Cancer Res 2010;70:86s.
10. Bergh J, Greil R, Voytko N, Makhson A, Cortes J, Lortholary A, Huang X, Giorgetti C, Kern KA, Lichinitser M: Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC). J Clin Oncol 2010;28:suppl; abstr LBA1010.
11. Crown J, Dieras V, Staroslawska E, Yardley DA, Davidson N, Bachelot TD, Tassell VR, Huang X, Kern KA, Romieu G: Phase III trial of suni-tinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC). J Clin Oncol 2010;28:suppl; abstr LBA1011.
12. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet;376:235-244.
13. Turner NC, Reis-Filho JS, Russell AM, Springall RJ, Ryder K, Steele D, Savage K, Gillett CE, Schmitt FC, Ashworth A, Tutt AN: BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007;26:2126-2132. (Pubitemid 46514749)
14. Turner N, Tutt A, Ashworth A: Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004;4:814-819. (Pubitemid 39331153)
15. O'Shaughnessy J, Osborne C, Pippen J, Yoffe M, Patt D, Monaghan G, Rocha C, Ossovskaya V, Sherman B, Bradley C: Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. ASCO Meet Abstr 2009;27:3.
16. Loibl S, Mueller B, Von Minckwitz G, Blohmer JU, du Bois A, Huober JB, Fend F, Budczies J, Denkert C: PARP expression in early breast cancer and its predictive value for response to neoadjuvant chemotherapy. J Clin Oncol 2010;28:suppl; abstr 10511.
17. Calvert AH: PARP as a therapeutic target. J Clin Oncol 2010;28:disc.
18. Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK: Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 2008;26:4282-4288.
19. Gadzicki D, Schubert A, Fischer C, Milde S, Lehmann U, Steinemann D, Luck HJ, Kreipe H, Schlegelberger B: Histopathological criteria and selection algorithms for BRCA1 genetic testing. Cancer Genet Cytogenet 2009;189:105-111.
20. Gelmon KA, Hirte HW, Robidoux A, Tonkin KS, Tischkowitz M, Swenerton K, Huntsman D, Carmichael J, Macpherson E, Oza AM: Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer. J Clin Oncol 2010;28:suppl; abstr 3002.
21. Dent R, Lindeman GJ, Clemons M, Wildiers H, Chan A, McCarthy NJ, Singer CF, Lowe ES, Kemsley K, Carmichael J: Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first-or second-line treatment of patients with metastatic triple-negative breast cancer: results from the safety cohort of a phase I/II multicenter trial. J Clin Oncol 2010;28:suppl; abstr 1018.
22. Isakoff SJ, Overmoyer B, Tung NM, Gelman RS, Giranda VL, Bernhard KM, Habin KR, Ellisen LW, Winer EP, Goss PE: A phase II trial of the PARP inhibitor veliparib (ABT888) and temo-zolomide for metastatic breast cancer. J Clin Oncol 2010;28:suppl; abstr 1019.
23. Lindström L, Howell S, Âström G, Wilking U, Lidbrink E, Armstrong A, Karlsson E, Hatschek T, Bergh J: Controversies in the management of metastatic breast cancer: biologic evaluation of breast cancer-should metastases be biopsied? J Clin Oncol 2010;28:e7.
24. Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, Albarracin C, Meric-Bernstam F, Woodward W, Theriault RL, Kiesel L, Hortobagyi GN, Pusztai L, Gonzalez-Angulo AM: Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 2009;20:1953-1958.
25. Amir E, Clemons M, Freedman OC, Miller N, Coleman RE, Purdie C, Jordan L, Quinlan P, Thompson AM: Tissue confirmation of disease recurrence in patients with breast cancer: pooled analysis of two large prospective studies. J Clin Oncol 2010;28:suppl; abstr 1007.